ArticleJournal of clinical microbiology2017
Evaluation of the Accelerate Pheno System for Fast Identification and Antimicrobial Susceptibility Testing from Positive Blood Cultures in Bloodstream Infections Caused by Gram-Negative Pathogens.
Article in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 165 citations in OpenAlex.
- Evaluation of an adapted relative growth method by MALDI-TOF MS for rapid determination of the susceptibility ofMicrobiology spectrum · 2026Article
- Association of a Hospital-Wide Integrated Stewardship Intervention with Hospital-Acquired Multidrug-Resistant Organism Infection Incidence Density: A Large-Scale Interrupted Time-Series Study.Antibiotics (Basel, Switzerland) · 2026Article
- Novel rapid diagnostic system for pathogen identification and antimicrobial susceptibility testing: clinical utility in ICU patients with sepsis.BMC infectious diseases · 2026Article
- Clinical performance of the VITEK REVEAL fast antimicrobial susceptibility test within a real-world workflow for gram-negative bacteremia: comparison with QMAC-dRAST and conventional methods.Microbiology spectrum · 2026Article
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Emerging technologies for rapid phenotypic antimicrobial susceptibility testing of clinical isolates of bacteria.Journal of clinical microbiology · 2025Review
- Digital holographic microscopy for rapid bacteria segmentation and counting in microfluidic cartridges: basic considerations and limitations for diagnostic application.Journal of biomedical optics · 2025Article
- Culture-free detection of bacteria from blood for rapid sepsis diagnosis.NPJ digital medicine · 2025Article
- Evaluation of FASTinov for rapid antimicrobial susceptibility testing in Pseudomonas aeruginosa.Scientific reports · 2025Article
- A simple, low-cost, and highly efficient protocol for rapid isolation of pathogenic bacteria from human blood.Frontiers in microbiology · 2025Article
- Delving into discrepancies, a single-center experience with Accelerate Pheno for gram-negative bacteremia, a rapid phenotypic susceptibility testing method.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Comprehensive pathogen identification and antimicrobial resistance prediction from positive blood cultures using nanopore sequencing technology.Genome medicine · 2024Article
- An investigation of scattered light integrating collector technology for rapid blood culture sensitivity testing.Journal of medical microbiology · 2024Article
- Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics.The Journal of antimicrobial chemotherapy · 2024Review
- Getting Up to Speed: Rapid Pathogen and Antimicrobial Resistance Diagnostics in Sepsis.Microorganisms · 2024Review
- Rapid Phenotypic and Genotypic Antimicrobial Susceptibility Testing Approaches for Use in the Clinical Laboratory.Antibiotics (Basel, Switzerland) · 2024Review
- Bacterial Infections in Intensive Care Units: Epidemiological and Microbiological Aspects.Antibiotics (Basel, Switzerland) · 2024Review
- Rapid AST: Possibility of inferring resistance mechanisms with complex phenotypes.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Article
- Biofilm antimicrobial susceptibility testing: where are we and where could we be going?Clinical microbiology reviews · 2023Review
- Rapid diagnostics to enhance therapy selection for the treatment of bacterial infections.Current pharmacology reports · 2023Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bloodstream infections (BSI) are an important cause of morbidity and mortality. Increasing rates of antimicrobial-resistant pathogens limit treatment options, prompting an empirical use of broad-range antibiotics. Fast and reliable diagnostic tools are needed to provide adequate therapy in a timely manner and to enable a de-escalation of treatment. The Accelerate Pheno system (Accelerate Diagnostics, USA) is a fully automated test system that performs both identification and antimicrobial susceptibility testing (AST) directly from positive blood cultures within approximately 7 h. In total, 115 episodes of BSI with Gram-negative bacteria were included in our study and compared to conventional culture-based methods. The Accelerate Pheno system correctly identified 88.7% (102 of 115) of all BSI episodes and 97.1% (102 of 105) of isolates that are covered by the system's identification panel. The Accelerate Pheno system generated an AST result for 91.3% (95 of 104) samples in which the Accelerate Pheno system identified a Gram-negative pathogen. The overall category agreement between the Accelerate Pheno system and culture-based AST was 96.4%, the rates for minor discrepancies 1.4%, major discrepancies 2.3%, and very major discrepancies 1.0%. Of note, ceftriaxone, piperacillin-tazobactam, and carbapenem resistance was correctly detected in blood culture specimens with extended-spectrum beta-lactamase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.